DM004 / Doma Pharma, Biocytogen - LARVOL DELTA

Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate (AACR 2023) - "In particular, DM004 Top2-MMAE outperformed benchmark ADCs in lung BP0508 PDX models. In summary, we have identified a novel BsADC which may be a promising future treatment for cancers co-expressing 5T4 and MET."

Late-breaking abstract • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • TOP1